natgillin/translations-raw huggingface dataset:
Hos kvinder med mangel på LH og FSH (hypogonadotropisk hypogonadisme) er formålet med Bemfola-behandling i forbindelse med lutropin alfa at udvikle en enkelt Graafsk follikel, fra hvilken en oocyt kan frigives efter administration af humant choriongonadotropin (hCG).
In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of Bemfola therapy in association with lutropin alfa is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG).
Hos kvinder med mangel på LH og FSH (hypogonadotropisk hypogonadisme), er formålet med GONAL-f behandling i forbindelse med lutropin alfa at udvikle en enkelt Graafsk follikel fra hvilken en oocyt kan frigives efter administration af humant choriongonadotropin (hCG).
In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of GONAL-f therapy in association with lutropin alfa is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG).
Hos kvinder med nylig eller aktuel tromboembolisk sygdom eller med kendt risiko for tromboemboliske hændelser, f.eks. i den personlige eller familiære anamnese, kan behandling med gonadotropiner øge risikoen for forværring eller forekomst af sådanne hændelser.
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events.
Hos kvinder med nylig eller aktuel tromboembolisk sygdom eller med kendt risiko for tromboemboliske hændelser, f.eks. i den personlige eller i familieanamnesen, kan behandling med gonadotropiner øge risikoen for forværring eller forekomst af sådanne hændelser.
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thrombo-embolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events.
Hos kvinder med osteoporose, som havde været gennem overgangsalderen, var Prolia mere effektivt end placebo til at mindske antallet af brud.
In women with osteoporosis who had been through the menopause, Prolia was more effective than placebo at reducing fractures.
Hos kvinder Ovarielt hyperstimulationssyndrom (OHSS)
In females Ovarian Hyperstimulation Syndrome (OHSS)
Hos kvinder på mellem 27 og 45 år forventes effekten af Gardasil 9 for de 4 oprindelige typer baseret på (1) høj effekt af qHPV- vaccine hos kvinder på mellem 16 og 45 år og (2) sammenlignelig immunogenicitet af Gardasil 9 og qHPV-vaccine hos piger og kvinder på mellem 9 og 26 år.
In women 27- through 45 years of age, efficacy of Gardasil 9 for the 4 original types is expected based on (1) high efficacy of qHPV vaccine in women 16- through 45 years of age and (2) comparable immunogenicity of Gardasil 9 and qHPV vaccine in girls and women 9- through 26 years of age.
Hos kvinder versus mænd var den gennemsnitlige halveringstid en del forlænget (36,7 versus
In female versus male subjects, the mean elimination half-life was somewhat prolonged (36.7 versus
Hos kvinder, der fik 200 mg etravirin to gange dagligt, blev der observeret højere middelværdier for Cmax, AUC12t og Cmin under graviditeten i forhold til post partum.
In women receiving etravirine 200 mg b.i.d., higher mean values for Cmax, AUC12h and Cmin were observed during pregnancy compared to postpartum.
Hos kvinder, der har nået overgangsalderen, er Senshio er påvist at give lindring af symptomerne på vulvovaginal atrofi ved sammenligning med placebo.
Senshio was shown to improve symptoms of vulvovaginal atrophy in postmenopausal women when compared with placebo.
Hos kvinder, der har nået overgangsalderen, falder indholdet af kønshormonet østrogen.
In women who have been through the menopause, levels of the sex hormone oestrogen fall.
Hos kvinder, der ved baseline havde BMD i lårbenshals på  -2,5, nedsatte Prolia risikoen for non-vertebral fraktur (35 % relativ risikoreduktion, 4,1 % absolut risikoreduktion, p < 0,001, eksploratorisk analyse).
In women with baseline femoral neck BMD  -2.5, Prolia reduced the risk of non-vertebral fracture (35% relative risk reduction, 4.1% absolute risk reduction, p < 0.001, exploratory analysis).
Hos kvinder, hvis endogene gonadotropin sekretion er undertrykt, har det ikke desto mindre vist sig, at follitropin alfa effektivt stimulerer follikeludviklingen og steroidgenesen, på trods af umålelige LH-værdier.
In women whose endogenous gonadotrophin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.
hos kvinder, når de er holdt op med at menstruere,
in postmenopausal women,
Hos kvinder, som har været gennem overgangsalderen, reducerer Prolia risikoen for brud i rygsøjlen og andre steder i kroppen, herunder hoften.
In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.
Hos kvæg
In cattle
Hos kvæg anvendes Inflacam i kombination med passende antibiotikabehandling til at mindske de kliniske sygdomssymptomer ved akut respiratorisk infektion (infektion i lunger og luftveje).
In cattle, Inflacam is used together with appropriate antibiotic therapy, to reduce clinical signs of disease in acute respiratory infection (infection of the lungs and airways).
Hos kvæg anvendes Meloxidyl som injektion mod akutte luftvejsinfektioner i kombination med relevant antibiotikabehandling for at reducere kliniske tegn, mod diarré i kombination med oral rehydreringsbehandling for at reducere kliniske tegn hos kalve, der er mere en én uge
In cattle Meloxidyl injection is used to reduce clinical signs in case of acute respiratory infection with appropriate antibiotic therapy, to reduce clinical signs in case of diarrhoea in combination with oral re-hydration therapy in calves over one week of age and young, non- lactating cattle and as supportive therapy in the treatment of acute mastitis, in combination with antibiotics.
Hos kvæg anvendes Metacam i kombination med passende antibiotikabehandling til mindskning af kliniske sygdomssymptomer ved akut (kortvarig) respiratorisk infektion (infektion i lunger og luftveje).
In cattle, Metacam is used together with appropriate antibiotic therapy, to reduce clinical signs of disease, in acute (short-term) respiratory infection (infection of the lungs and airways).
Hos kvæg anvendes Rheumocam i kombination med passende antibiotikabehandling til at mindske de kliniske sygdomssymptomer ved akut respiratorisk infektion (infektion i lunger og luftveje).
In cattle, Rheumocam is used together with appropriate antibiotic therapy, to reduce clinical signs of disease, in acute respiratory infection (infection of the lungs and airways).
Hos kvæg blev sikkerheden under drægtighed ekstrapoleret fra en undersøgelse, som blev udført hos drægtige køer med en vaccine lig Bluevac BTV8 indeholdende en anden serotype (serotype 1).
In cattle, safety during pregnancy was extrapolated from a study that was conducted in pregnant cows with a similar vaccine to Bluevac BTV8 which contained a different serotype (serotype 1).
Hos kvæg bør det volumen, der injiceres pr. injektionssted, ikke overstige 7 ml.
In cattle, the volume administered per injection site should not exceed 7 ml.
Hos kvæg doseret med 5-6 gange anbefalet dosis er observeret mild myokardie- degeneration.
Mild myocardial degeneration has been observed in cattle receiving 5 to 6 times the recommended dose.
Hos kvæg efter administration af en dobbeltdosis efterfulgt af en enkeltdosis 7 uger senere og en tredje vaccination med en enkelt dosis 13 uger efter den anden dosis.
in cattle following administration of a double dose followed by a single dose 7 weeks later and a third vaccination with a single dose 13 weeks after the second dose,
Hos kvæg er ceftiofur aktivt over for følgende mikroorganismer, som er involveret i akut post-partum (puerperal) metritis: Escherichia coli, Arcanobacterium pyogenes og Fusobacterium necrophorum, og interdigital necrobacillose: Bacteroides spp., Fusobacterium necrophorum, Porphyromonas spp. og Prevotella spp.
In cattle, ceftiofur is active against the following micro-organisms which are involved in acute post- partum (puerperal) metritis: Escherichia coli, Arcanobacterium pyogenes and Fusobacterium necrophorum; and interdigital necrobacillosis: Bacteroides spp., Fusobacterium necrophorum, Porphyromonas spp. and Prevotella spp.
Hos kvæg er der i laboratorieforsøg observeret en let, forbigående og smertefri hævelse på injektionsstedet for de fleste dyr.
In cattle a slight transient painless swelling at the injection site was observed in most animals in laboratory studies.
Hos kvæg og får
In cattle and sheep
Hos kvæg og får:
In cattle and sheep
Hos kvæg og geder kan vaccinen anvendes under laktation.
In cattle and goats the vaccine can be used during lactation.
Hos kvæg, var den farmakokinetiske profil af tulathromycin efter en enkel subkutan applikation af 2,5 mg pr. kg legemsvægt, karakteriseret af hurtig og fuldstændigt absorption efterfulgt af en høj fordeling og langsom udskillelse.
In cattle, the pharmacokinetic profile of tulathromycin when administered as a single subcutaneous dose of 2.5 mg/kg bodyweight, was characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Hos kyllinger absorberes difloxacin næsten fuldstændigt efter oral indgift (ca.
In chickens difloxacin is nearly completely absorbed after oral administration (approx.
Hos kyllinger og kalkuner er Dicural indiceret til behandling af kroniske luftvejsinfektioner forårsaget af difloxacin-følsomme stammer af Escherichia coli og Mycoplasma gallisepticum.
In chickens and turkeys: Dicural oral solution is indicated for treatment of chronic respiratory infections caused by sensitive strains of Escherichia coli and Mycoplasma gallisepticum.
Hos kyllinger og ænder viste administration af dobbeltdosis ingen anden effekt end efter administration af en enkeltdosis (se punkt 4.6).
Following the administration of a double dose in chickens and ducks, no adverse reactions other than those described in section 4.6 have been observed.
Hos kyllinger og ænder viste administration af dobbeltdosis ingen anden effekt end efter administration af en enkeltdosis.
Following the administration of a double dose in chickens and ducks, no adverse reactions other than those described in section 6 have been observed.
Hos kyllinger:
In chickens:
Hos køer, som forventes at være fri for subklinisk mastitis ved goldning, i hvilke brug af antibiotika ikke er berettiget/tilladt, kan Velactis anvendes som en afgoldningsbehandling.
For cows considered likely to be free of subclinical mastitis at drying off, in which antibiotic use is not justified/permitted, Velactis can be used as a dry cow treatment.
Hos lakterende rotter er koncentrationen af 35S-enoxaparin og dets mærkede metabolitter meget lav i mælk.
In lactating rats, the concentration of 35S-enoxaparin or its labelled metabolites in milk is very low.
Hos lam (ca.
In lambs (approx.
Hos langsomme CYP2D6-omsættere kan samtidig brug af potente CYP3A4-hæmmere medføre højere plasmakoncentrationer af aripiprazol end hos ekstensive CYP2D6-omsættere.
In CYP2D6 poor metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.
Hos langsomme CYP2D6-omsættere kan samtidig brug af potente CYP3A4-hæmmere medføre højere plasmakoncentrationer af Aripiprazole end hos ekstensive CYP2D6-omsættere.
In CYP2D6 poor metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.
Hos langsomme CYP2D6-omsættere skal start- og vedligeholdelsesdosis være 300 mg.
In patients who are known to be CYP2D6 poor metabolisers, the starting and maintenance dose should be 300 mg.
Hos langsomme metabolisatorer (PM’er)
In poor metabolisers (PMs):
Hos levertransplanterede patienter var MPA-AUC-værdierne efter i.v. administration af CellCept (1 g to gange daglig) efterfulgt af 1,5 g to gange daglig oralt sammenlignelige med værdierne hos nyretransplanterede patienter, der fik oral CellCept (1 g CellCept to gange daglig).
In hepatic transplant patients, administration of 1 g BID intravenous CellCept followed by 1.5 g BID oral CellCept resulted in MPA AUC values similar to those found in renal transplant patients administered 1 g CellCept BID.
Hos levertransplanterede patienter, der indledningsvis blev behandlet med mycophenolatmofetil og tacrolimus samtidigt, blev MPAs Cmax og AUC – mycophenolatmofetils aktive metabolit - ikke signifikant påvirket af den samtidige administration af tacrolimus.
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus.
Hos levertransplanterede patienter, der indledningsvis blev behandlet med mycophenolatmofetil og tacrolimus samtidigt, blev MPA’s Cmax og AUC – mycophenolatmofetils aktive metabolit - ikke signifikant påvirket af den samtidige administration af tacrolimus.
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus.
Hos mandlige pædiatriske Fabry- patienter faldt plasma-Gb3 40-50% efter 6 måneders behandling med Replagal 0,2 mg/kg, og denne reduktion varede ved hos 11 patienter efter i alt 4 års behandling.
In male paediatric Fabry patients plasma Gb3 decreased 40-50% after 6 months of Replagal therapy 0.2 mg/kg and this reduction persisted after a total 4 years of treatment in 11 patients.
Hos mandlige pædiatriske patienter i alderen 7 år og derover var variabiliteten i hjertefrekvens unormal ved baseline og forbedredes efter 6 måneders behandling med Replagal hos 15 drenge.
In male paediatric patients ≥ 7 years of age, heart rate variability was abnormal at baseline and improved after 6 months of Replagal therapy in 15 boys and the improvement was sustained through
Hos mange patienter ses tegn på adrenerg modregulation forud for tegn og symptomer på neuro- glykopeni.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation.
Hos mange patienter ses tegn på adrenerg modregulation forud for tegn og symptomer på neuroglycopeni.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation.
Hos mdr1 muntat (-/-) af Colli, Shelti og Australsk Hyrdehund kan symptomer på neurologiske reaktioner (f.eks. kramper) desuden være kraftigere.
In addition, signs of neurological disorders may be more severe (e.g. convulsion) in mdr1 mutant (-/-) Collies, Shelties and Australian Shepherds.
Hos mdr1 mutant (-/-) Collier, er sikkerhedsmargen lavere end sammenlignet med en normal hundepopulation, og milde forbigående tremor og/eller ataxi er set i enkelte tilfælde efter overdosis på 2 gange den rekommanderede dosis hos hunder, der var fastende som anbefalet..
In mdr1 mutant (-/-) Collies the margin of safety appears lower compared to the normal dog population, with mild transient tremor and/or ataxia occasionally observed after twice the recommended dose, in dogs fasted as recommended.
Hos meget små børn kan vaccinen gives i lårmusklen.
In very small children, the injection may be given into the thigh muscle.
Hos meget tidligt fødte børn (født i uge 28 eller tidligere i svangerskabet) kan længere mellemrum mellem vejrtrækningerne forekomme i 2-3 dage efter vaccinationen.
In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.
Hos meget tidligt fødte spædbørn (28 ugers graviditet eller før) kan der gå længere tid end normalt mellem åndedragene i 2 – 3 dage efter vaccination.
In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2 - 3 days after vaccination.
Hos mennesker er der ingen evidens for, at enoxaparin passerer placentabarrieren under andet trimester af graviditeten.
In humans, there is no evidence that enoxaparin crosses the placental barrier during the second trimester of pregnancy.
Hos mennesker er der udført to studier med positron-emissiontomografi (PET-studier) med 5-HT- transportørligander (11C-MADAM eller 11C-DASB) for at kvantificere 5-HT-transportørbindingen i hjernen ved forskellige dosisniveauer.
In humans, two positron emission tomography (PET) studies have been conducted using 5-HT transporter ligands (11C-MADAM or 11C-DASB) to quantify the 5-HT transporter occupancy in the brain across different dose levels.
Hos mennesker er det tilsyneladende terminale fordelingsvolumen mindst 90 liter og det estimeres, at 40-50 % af den cirkulerende dosis bindes til knoglerne.
In humans, the apparent terminal volume of distribution is at least 90 l and the amount of dose reaching the bone is estimated to be 40 – 50 % of the circulating dose.
Hos mennesker er det tilsyneladende terminale fordelingsvolumen mindst 90 liter, og det estimeres, at 40-50 % af den cirkulerende dosis bindes til knoglerne.
In humans, the apparent terminal volume of distribution is at least 90 l and the amount of dose reaching the bone is estimated to be 40-50 % of the circulating dose.
Hos mennesker er det tilsyneladende terminale fordelingsvolumen mindst 90 liter, og det estimeres, at 40-50% af den cirkulerende dosis bindes til knoglerne.
In humans, the apparent terminal volume of distribution is at least 90 l and the amount of dose reaching the bone is estimated to be 40-50% of the circulating dose.
Hos mennesker har der været enkelte tilfælde, hvor rester blev observeret som tilfældige fund uden tegn på svækkelse af virkningen.
From the experience in humans there have been isolated cases where remnants were observed as coincidental findings with no signs of functional impairment
Hos mennesker har Thymanax positive faseændrende egenskaber, idet det fremskynder indsovningstid, fald i legemstemperatur og frigivelse af melatonin.
In humans, Thymanax has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.
Hos mennesker har Valdoxan positive faseændrende egenskaber, idet det fremskynder indsovningstid, fald i legemstemperatur og frigivelse af melatonin.
In humans, Valdoxan has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.
Hos mennesker kan itraconazol hæmme omsætningen af lægemidler, der omdannes af cytokrom 3A- isoenzymer, f.eks. chloramphenicol, ivermectin og methylprednisolon.
In humans it is known that itraconazole can inhibit the metabolism of medicinal products that are substrates for cytochrome 3A isoenzymes, for example, chloramphenicol, ivermectin or methylprednisolone.
Hos mennesker kan kombinationen af ACE-hæmmere og non-steroide antiinflammatorika (NSAID'er) medføre reduceret anti-hypertensiv virkning eller svækket nyrefunktion.
In man, the combination of angiotensin converting enzyme (ACE) inhibitors and non-steroidal anti- inflammatory drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function.
Hos mennesker kan tacrolimus farmakokinetik efter intravenøs infusion bedst beskrives med en to- compartment model.
In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.
Hos mennesker kan tacrolimus’ farmakokinetik efter intravenøs infusion bedst beskrives med en to- compartment model.
In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.
Hos mennesker kunne mindre end 1- 5 % af dosis måles som uomdannet stof i hhv. fæces og urin efter 2 ugers indsamling, hvilket er tegn på, at oritavancin udskilles langsomt og uomdannet.
In humans, less than 1% to 5% of the dose was recovered as parent drug in faeces and urine respectively after 2 weeks of collection indicating that oritavancin is slowly excreted unchanged.
Hos mennesker metaboliseres dimethylfumarat ekstensivt af esteraser, inden det når systemkredsløbet, og der sker en yderligere metabolisering vha. tricarboxylsyrecyklussen uden involvering af CYP- systemet.
In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system.
Hos mennesker omfatter de mest almindelige symptomer forbundet med overdosering krampeanfald, somnolens, kvalme, takykardi og opkastning.
In humans, the most common symptoms associated with overdosage include seizures, somnolence, nausea, tachycardia, and vomiting.
Hos mennesker omfatter de mest almindelige symptomer, der er forbundet med overdosering krampeanfald, somnolens, kvalme, takykardi og opkastning.
In humans, the most common symptoms associated with overdose include seizures, somnolence, nausea, tachycardia, and vomiting.
Hos mennesker påvirker føde amifampridins absorptionshastighed og absorptionsfraktion (se Tabel 2).
In humans, the rate and extent of absorption of amifampridine is influenced by food (See Table 2).
Hos mennesker synes PDE5- hæmmere ikke at påvirke blødningstiden, hvad enten de anvendes alene eller i kombination med acetylsalicylsyre.
In humans, PDE5 inhibitors do not appear to affect bleeding time alone or in combination with acetylsalicylic acid.
Hos mennesker udgjorde brinzolamid og
In humans, urinary brinzolamide and
Hos mennesker øger brugen af sevofluran både intensiteten og varigheden af den neuromuskulære blokade fremkaldt af non-depolariserende muskelrelaksantia.
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Hos mennesket har virkning ved tilstande med både partiel og generaliseret epilepsi (epileptiforme afladninger/fotoparoxysmalt respons) bekræftet den bredspektrede farmakologiske profil af levetiracetam.
In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/ photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.
Hos mennesket hæmmer en dosis på 80 mg telmisartan næsten fuldstændigt en angiotensin II- provokeret blodtryksforhøjelse.
In human, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase.
Hos mere end 20% af patienterne i nyrecellekarcinom- og mantlecellelymfonstudierne sås bivirkninger (alle grader), der inkluderer anæmi, kvalme, udslæt (herunder udslæt, kløende udslæt, maculopapuløst udslæt, pustulært udslæt), nedsat appetit, ødem, asteni, udtalt træthed, hyperglykæmi, hyperkolesterolæmi, dysgeusi, kløe, hoste, infektion, pneumoni, dyspnø.
The adverse reactions (all grades) experienced by at least 20% of the patients in renal cell carcinoma and mantle cell lymphoma registration studies include anaemia, nausea, rash (including rash, pruritic rash, maculopapular rash, pustular rash), decreased appetite, oedema asthenia, fatigue, thrombocytopaenia, diarrhoea, pyrexia, epistaxis, mucosal inflammation, stomatitis, vomiting, hyperglycemia, hypercholesterolemia, dysgeusia, pruritus, cough, infection, pneumonia, dyspnoea.
Hos mindst 12 patienter, der behøvede en større operation under undersøgelsen, blev kontrollen med blodtabet også bedømt som god eller udmærket af patientens læge.
In 12 patients who required major surgery during the study, control of blood loss was also rated as good or excellent by the patients’ doctors.